Vidofludimus – 5 mg

Brand:
Cayman
CAS:
717824-30-1
Storage:
-20
UN-No:
Non-Hazardous - /

Dihydroorotate dehydrogenase (DHODH) is involved in pyrimidine nucleoside biosynthesis. DHODH inhibitors have value in autoimmune diseases as well as cancer and certain infections.{31187} Vidofludimus is an immunosuppressive drug that inhibits DHODH (IC50s = 0.134, 1.29, and 10.6 µM for human, rat, and mouse isoforms, respectively).{31185,31186} Through this action, it inhibits the proliferation of T cells and B cells and the secretion of IL-17 (IC50s = 12.9, 3.7, and 6.0 µM, respectively, in human cells).{31185,31186} Oral administration of vidofludimus improves both chronic dextran sodium sulfate-induced and acute TNBS-induced colitis in mice.{31185}  

 

Available on backorder

SKU: - Category:

Description

An immunosuppressive drug that inhibits DHODH (IC50s = 0.134, 1.29, and 10.6 µM for human, rat, and mouse isoforms, respectively); inhibits the proliferation of T cells and B cells and the secretion of IL-17 (IC50s = 12.9, 3.7, and 6.0 µM, respectively, in human cells)


Formal name: 2-[[(3-fluoro-3′-methoxy[1,1′-biphenyl]-4-yl)amino]carbonyl]-1-cyclopentene-1-carboxylic acid

Synonyms:  4SC-101

Molecular weight: 355.4

CAS: 717824-30-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Gastric Disease|Crohn’s Disease||Research Area|Immunology & Inflammation|Gastric Disease|Ulcerative Colitis||Research Area|Immunology & Inflammation|Immunosuppressants